Whilst there was a lot of frustration and disbelief at the time of the capital raising, I think in time it will be seen as the right and best thing the company could have done.
Sure it could have been done at a higher price, less dilution, although it is what it is.
Now that the company's capital position is secured and the next raising a long way off I am looking forward to seeing the company re-rate accordingly on Phase 1 commencement and IF it achieves safe Phase 1 results. I am confident they will (based on pre-clinical) results.
Big future ahead for this company and it is just the beginning.
Ann: Ethics Application Submitted for Phase 1 Trial, page-7
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
71.0¢ |
Change
-0.040(5.33%) |
Mkt cap ! $90.94M | |||
| Open | High | Low | Value | Volume |
| 73.0¢ | 73.0¢ | 70.5¢ | $123.8K | 170.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 22605 | 70.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 75.0¢ | 5791 | 2 |
View Market Depth
| Last trade - 15.58pm 28/10/2024 (20 minute delay) ? |
| AGN (ASX) Chart |